Loading...
AIRS logo

AirSculpt Technologies, Inc.NasdaqGM:AIRS Voorraadrapport

Marktkapitalisatie US$371.1m
Prijs aandeel
US$5.33
US$6
11.2% ondergewaardeerd intrinsieke korting
1Y25.4%
7D11.0%
1D
Portefeuillewaarde
​
Bekijk

AirSculpt Technologies, Inc.

NasdaqGM:AIRS Voorraadrapport

Marktkapitalisatie: US$371.1m

AirSculpt Technologies (AIRS) Aandelenoverzicht

AirSculpt Technologies, Inc. richt zich, samen met haar dochterondernemingen, op het opereren als een holdingmaatschappij voor EBS Intermediate Parent LLC die diensten levert op het gebied van lichaamscontouringprocedures in de Verenigde Staten en Canada. Meer informatie

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden vergeleken met de US markt

Aandeelhouders zijn het afgelopen jaar verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.


AIRS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

AirSculpt Technologies, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor AirSculpt Technologies
Historische aandelenkoersen
Huidige aandelenkoersUS$5.33
52 Week HoogtepuntUS$12.00
52 Week LaagUS$1.51
Bèta2.02
1 maand verandering98.88%
3 maanden verandering183.51%
1 Jaar Verandering25.41%
3 jaar verandering-29.22%
5 jaar veranderingn/a
Verandering sinds IPO-66.46%

Recent nieuws en updates

Recent updates

Analyseartikel • Jan 06

AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) Share Price Is Still Matching Investor Opinion Despite 35% Slump

Unfortunately for some shareholders, the AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) share price has dived 35% in the...
Seeking Alpha • Oct 29

AirSculpt Technologies: Upgrading To Buy On Improving Fundamentals

Summary Upgrade AirSculpt Technologies (AIRS) to 'Buy' as strong technical momentum and record lead generation drive optimism for further upside. AIRS delivered positive sequential growth in Q2, with improved gross margins, reduced SG&A expenses, and lower customer acquisition costs supporting profitability. Debt reduction and the highest operating cash flow in eight quarters position AIRS closer to sustained profitability, despite macro risks and elevated valuation. Q3 earnings are critical; AIRS must meet or exceed $39.8 million in revenue to maintain momentum and justify its premium sales multiple. Read the full article on Seeking Alpha
Analyseartikel • Oct 05

AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) Shares Climb 32% But Its Business Is Yet to Catch Up

Despite an already strong run, AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares have been powering on, with a gain...
Analyseartikel • Sep 24

Estimating The Intrinsic Value Of AirSculpt Technologies, Inc. (NASDAQ:AIRS)

Key Insights AirSculpt Technologies' estimated fair value is US$7.56 based on 2 Stage Free Cash Flow to Equity...
Analyseartikel • Aug 29

Here's Why AirSculpt Technologies (NASDAQ:AIRS) Can Afford Some Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analyseartikel • Jul 25

AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) 28% Share Price Surge Not Quite Adding Up

Despite an already strong run, AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares have been powering on, with a gain...
Analyseartikel • Jun 10

AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) Shares Climb 69% But Its Business Is Yet to Catch Up

The AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) share price has done very well over the last month, posting an...
Analyseartikel • Apr 25

Some Confidence Is Lacking In AirSculpt Technologies, Inc. (NASDAQ:AIRS) As Shares Slide 31%

To the annoyance of some shareholders, AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares are down a considerable 31...
Analyseartikel • Feb 25

AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) Share Price Matching Investor Opinion

It's not a stretch to say that AirSculpt Technologies, Inc.'s ( NASDAQ:AIRS ) price-to-sales (or "P/S") ratio of 1.4x...
Analyseartikel • Jan 28

Investors Could Be Concerned With AirSculpt Technologies' (NASDAQ:AIRS) Returns On Capital

Ignoring the stock price of a company, what are the underlying trends that tell us a business is past the growth phase...
Analyseartikel • Dec 04

An Intrinsic Calculation For AirSculpt Technologies, Inc. (NASDAQ:AIRS) Suggests It's 40% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, AirSculpt Technologies fair value estimate is US$12.46 Current...
Analyseartikel • Nov 14

Why Investors Shouldn't Be Surprised By AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) 30% Share Price Surge

Despite an already strong run, AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares have been powering on, with a gain...
Analyseartikel • Nov 07

Is AirSculpt Technologies (NASDAQ:AIRS) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analyseartikel • Oct 20

The Return Trends At AirSculpt Technologies (NASDAQ:AIRS) Look Promising

There are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...
Analyseartikel • Sep 28

Optimistic Investors Push AirSculpt Technologies, Inc. (NASDAQ:AIRS) Shares Up 29% But Growth Is Lacking

AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shareholders have had their patience rewarded with a 29% share price jump...
Analyseartikel • Sep 25

Is It Time To Consider Buying AirSculpt Technologies, Inc. (NASDAQ:AIRS)?

AirSculpt Technologies, Inc. ( NASDAQ:AIRS ), might not be a large cap stock, but it saw a significant share price rise...
Analyseartikel • Aug 01

The Market Lifts AirSculpt Technologies, Inc. (NASDAQ:AIRS) Shares 26% But It Can Do More

Those holding AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares would be relieved that the share price has rebounded...
Analyseartikel • Apr 04

There's Been No Shortage Of Growth Recently For AirSculpt Technologies' (NASDAQ:AIRS) Returns On Capital

What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Analyseartikel • Feb 23

Here's Why AirSculpt Technologies (NASDAQ:AIRS) Can Manage Its Debt Responsibly

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analyseartikel • Dec 14

AirSculpt Technologies, Inc. (NASDAQ:AIRS) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable

AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shareholders are no doubt pleased to see that the share price has bounced...
Analyseartikel • Nov 12

US$8.19: That's What Analysts Think AirSculpt Technologies, Inc. (NASDAQ:AIRS) Is Worth After Its Latest Results

There's been a notable change in appetite for AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares in the week since its...
Analyseartikel • Sep 20

Be Wary Of AirSculpt Technologies (NASDAQ:AIRS) And Its Returns On Capital

When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...
Analyseartikel • Oct 29

Capital Allocation Trends At AirSculpt Technologies (NASDAQ:AIRS) Aren't Ideal

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...
Seeking Alpha • Aug 27

AirSculpt Technologies: Niche Offering Offset By Profitability, Valuation

Summary AirSculpt Technologies presents with a unique offering with exposure to alternative medical sectors in cosmetics. The company's growth strategy is well received but comes with notable execution risks. Shares appear to be reasonably valued at current levels, however, deeper examination of financials places questions on just what we are buying. With these points in mind, we value AIRS a hold. Investment summary AirSculpt Technologies, Inc. (AIRS) has piqued our interest since listing back in FY21. It operates in a novel segment of 'body contouring procedures' and is best known for its AirSculpt procedure, under the subsidiary brand Elite Body Sculpture. The proprietary procedure is touted due to its minimally invasive nature that contrasts to traditional liposuction. Its growth strategy is to open new centres and expand/relocate existing ones, ultimately driving up revenue per case, cases per room and overall case numbers as part of its growth strategy. Exhibit 1. AIRS 6-month price action Data: Refinitiv Eikon Despite the allure, forensics over its financial statements reveal there to be a loose fit to the kind of equity premia we are seeking exposure to in H2 FY22. Valuations are supportive of a neutral view and regulatory headwinds in adjacent markets [Australia, to be specific] has us cautious on the ramifications for global peers. With these points in mind, we rate AIRS a hold. Q2 earnings indicate growth trends We see the differentiated strengths of AIRS' procedures in its most recent earnings, with upsides to consensus at the top and bottom lines. Forecasts on the global cosmetic market growth published in April 2022 predict a geometric growth of 3.6% per year from 2021 until 2028. Contrary evidence suggests a 9.6% CAGR into 2030. AIRS printed revenue of $49.7 million for the period, up 42% YoY. Presuming either of the above forecasts are true, then AIRS above top-line growth suggest it gained additional market share during the quarter. As a side note, however, this is a murky segment - recent controversies in the Australian cosmetic surgery market surrounding regulation are a potential risk for global participants. Cases also increased 22.5% YoY to 3,691 total cases, as seen in Exhibit 2. The company records each case as 1 visit, with doesn't factor in that each patient may have multiple treatment areas per visit. Nevertheless, it opened 4 new centres during Q2 FY21, bringing total centres to 19. Meanwhile, revenue per case increased 16% YoY to ~$13,450, supported by the company's access to 38 procedure rooms versus 25 the year prior. However, the 10-Q did note that cases per procedure room declined due to the addition of the 13 new centres and expansion of existing ones, versus an organic decline over the 12 months. There is good reason to estimate that trends will normalize as procedures per room level to overall company growth trends. Exhibit 2. Above-market growth statistics imply the company might be gaining additional market share Image: HB Insights, AIRS SEC Filings Despite the upsides in booked revenues for the quarter, our findings indicate there are drains and pulls on liquidity that may place stress on AIRS' current position. As seen below, we estimate there to be around 3-4 quarters of cash runway remaining with the company's most recent earnings. It needs a substantial growth in cash conversion from net income to bolster its position here and prevent additional dilutive equity raise(s) and/or expensive debt issuance/origination in the high yield debt capital markets. Noteworthy to this point, however, is the company declared a $0.41/share special dividend to be paid in September. Exhibit 3. Data: HB Insights Estimates The company also reports non-GAAP EBITDA and recorded a $1.01 million YoY increase to $15.2 million as seen in Exhibit 4. This is despite earnings narrowing by 94% YoY from ~$10 million to $583,000. According to the 10-Q, "management assesses and believes investors should assess our operating performance" [using non-GAAP EBITDA]. We take some issue with this recommendation. Firstly, the company booked ~$7.3 million in stock-based compensation ("SBC") for the period, and saw an interest expense of $1.5 million - each up substantially on the year. Moreover, as seen below, AIRS asks us to ignore the impact of new centre opening and relocation costs, plus the SBC, plus the loss on asset disposals. We argue these are expenses that must be realized in the analysis of free cash flow and valuation. We can't simply ignore that these 3 expenses in particular total to $9.3 million, and removing them from the equation, non-GAAP EBITDA is ~$5.9 million. Not to mention, it also recorded a $60 million payment to its parent organization. Therefore, whilst it converted $8.5 million in quarterly cash flow, this was more than offset by these expenditures. Exhibit 4. Non-GAAP EBITDA includes several expenditures that we argue should be included in cash flow analysis Data: AIRS 10-Q, Q2 FY2022 Valuation AIRS' growth strategy involves opening de novo centres, expanding existing ones and acquiring additional assets into its portfolio. In that regard, AIRS' corporate value stems from its popular set of procedures - particularly AirSculpt liposuction - as an intangible plus its tangible book value. Any value manager will also familiarize this information with cash flow multiples and forecasts.
Seeking Alpha • Aug 12

AirSculpt Technologies reports Q2 earnings beat; reaffirms FY22 guidance

AirSculpt Technologies press release (NASDAQ:AIRS): Q2 GAAP EPS of $0.01 beats by $0.01. Revenue of $49.7M (+42.1% Y/Y) beats by $4.79M. Same-center cases and revenue per case for the second quarter of 2022 were up 4.7% and 15.0%, respectively, over the prior year period. For the second quarter of 2022, the company’s adjusted EBITDA grew 7.1% to $15.2M as compared to $14.2M for the prior year period. The company is reiterating its revenue outlook of $175-179 million vs. consensus of $177.40M and its Adjusted EBITDA guidance in the range of $58 - $60 million. The Company has opened two centers in 2022 and anticipates opening two additional centers in the second half of the year.

Rendement voor aandeelhouders

AIRSUS HealthcareUS Markt
7D11.0%-0.4%1.0%
1Y25.4%16.3%28.7%

Rendement versus industrie: AIRS overtrof de US Healthcare industrie, die het afgelopen jaar een rendement 16.3 % opleverde.

Rendement versus markt: AIRS presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 28.7 % opleverde.

Prijsvolatiliteit

Is AIRS's price volatile compared to industry and market?
AIRS volatility
AIRS Average Weekly Movement21.3%
Healthcare Industry Average Movement7.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stabiele aandelenkoers: De aandelenkoers van AIRS is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 21% ) van AIRS is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2012347Yogi Jashnaniwww.airsculpt.com

AirSculpt Technologies, Inc. richt zich, samen met haar dochterondernemingen, op het opereren als een holdingmaatschappij voor EBS Intermediate Parent LLC die diensten levert op het gebied van lichaamscontouringprocedures in de Verenigde Staten en Canada. Het bedrijf biedt AirSculpt aan, een lichaamscontouringbehandeling die vet verwijdert en de huid strakker maakt, terwijl het doelgebieden van het lichaam beeldhouwt in een minimaal invasieve procedure. Het biedt ook AirSculpt+, een procedure die permanent vet verwijdert en de huid strakker maakt met ongeëvenaarde precisie en finesse; en AirSculpt Smooth, een geavanceerd middel voor cellulitisverwijdering.

AirSculpt Technologies, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van AirSculpt Technologies zich tot de beurswaarde?
AIRS fundamentele statistieken
MarktkapitalisatieUS$371.07m
Inkomsten(TTM)-US$11.22m
Inkomsten(TTM)US$151.84m
2.5x
P/S-verhouding
-33.5x
Koers/Winstverhouding

Is AIRS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AIRS resultatenrekening (TTM)
InkomstenUS$151.84m
Kosten van inkomstenUS$51.53m
BrutowinstUS$100.31m
Overige uitgavenUS$111.53m
Inkomsten-US$11.22m

Laatst gerapporteerde inkomsten

Mar 31, 2026

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-0.16
Brutomarge66.06%
Nettowinstmarge-7.39%
Schuld/Eigen Vermogen Verhouding44.7%

Hoe presteerde AIRS op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/22 15:48
Aandelenkoers aan het einde van de dag2026/05/22 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

AirSculpt Technologies, Inc. wordt gevolgd door 6 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Michael GormanBTIG
Sam EiberBTIG
Benjamin MayoLeerink Partners LLC